Corcept Therapeutics Incorporated (CORT) has seen gains following FDA approval for its product, though some questions regarding the company's future prospects reportedly remain.

Corcept Therapeutics stock experienced a significant surge on Wednesday, driven by strong investor confidence. The reasons behind this sudden increase are being analyzed by market observers.

A preview of Corcept Therapeutics' financial results for the fourth quarter of 2025 has been released.

Corcept Therapeutics saw its stock price increase by nearly 9% this week, attracting attention from investors.

Corcept Therapeutics shares surged after its lead drug received approval from the FDA for the treatment of ovarian cancer, marking a significant milestone for the company.

The deadline to lead a securities class action lawsuit against Corcept Therapeutics, Inc. (CORT) is April 21, 2026, with Kaplan Fox available for contact.

Corcept Therapeutics' stock declined after an appeals court ruled in favor of Teva Pharmaceuticals in a patent dispute concerning Corcept's drug Korlym.

Corcept Therapeutics (CORT) shares climbed by 19.7% after its drug Lifyorli received approval from the FDA.

Corcept Therapeutics has been granted FDA approval for its new cancer therapy, marking a significant development in its oncology pipeline.

An analysis explores whether Corcept Therapeutics (CORT) is reaching a critical turning point in its market performance.

Multiple biotech and pharmaceutical companies, including Legend Biotech, Corcept Therapeutics, and Ultragenyx, have released updates on their drug pipelines, clinical trial data, and regulatory interactions, impacting market outlook.